Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis

Janus, Nicolas; Launay-Vacher, Vincent

doi:10.1080/17425255.2017.1292252

Cited by 5 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, only few cases were reported over times with no clear evidence of clinical outcomes [12,31]. As a consequence, it seems to be more a theoretical risk in thrombosis, but it is also important to consider the profile of the patients and more importantly the renal function and the nutrition status [32,33].…”

Section: Pharmacokinetic Ddis and Drug Transporter Ddismentioning

confidence: 99%

Complexity and clinical significance of drug–drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT)

Tsoukalas

Brito-Dellan²,

Font³

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

Cancer patients have an increased risk of developing venous thromboembolic events. Anticoagulation management includes prophylactic or therapeutic doses of low molecular weight heparins (LMWHs) or direct oral anticoagulants (DOACs). However, the management of thrombosis in patients with cancer is complex due to various individual and disease-related factors, including drug–drug interactions (DDIs). Furthermore, DDIs may impact both, cancer and venous thrombosis, treatment effectiveness and safety; their relevance is highlighted by the advances in cancer therapeutics. Given that these new oncology drugs are extensively used, more attention should be given to monitoring potential DDIs to minimize risks. Recognition of DDIs is of utmost importance in an era of rapid developments in cancer treatments and introduction of novel treatments and protocols. When managing cancer-associated thrombosis (CAT), the concomitant use of a DOAC and a moderate or strong modulator (inhibitor or inducer) of CYP3A4 or a P-glycoprotein (P-gp) is most likely to be associated with significant DDIs. Therefore, LMWHs remain the first-line option for the long-term management of CAT under these circumstances and physicians must consider utilizing LMWHs as first line. This review describes the risk of DDIs and their potential impact and outcomes in patients with cancer associated thrombosis (CAT) receiving anticoagulation. The DDIs explored include pharmacodynamics, pharmacokinetics, the breast cancer resistance protein (BCRP), and human plasma protein DDIs.

show abstract

Section: Pharmacokinetic Ddis and Drug Transporter Ddismentioning

confidence: 99%

Complexity and clinical significance of drug–drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT)

Tsoukalas

Brito-Dellan²,

Font³

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Khosravan et al [35] conducted a phase 1, single-dose study to study the PK of sunitinib at a dose of 50 mg and found that exposure of receptor tyrosine kinase inhibitor sunitinib was decreased in subjects that had end-stage renal disease potentially leading to lower efficacy. Janus and Launay-Vacher [36] have excellently reviewed elsewhere why clinicians need to be aware of the need to individualize treatment in hemodialysis patients who are increasingly being prescribed anticancer drugs.…”

Section: 0 Clinical Pharmacometrics For Cancer Precision Medicinementioning

confidence: 99%

Emerging Roles for Clinical Pharmacometrics in Cancer Precision Medicine

Nair

Kong

2018

Curr Pharmacol Rep

View full text Add to dashboard Cite

Purpose of review Although significant progress has been made in cancer research, there exist unmet needs in patient care as reflected by the ‘Cancer Moonshot’ goals. This review appreciates the potential utility of quantitative pharmacology in cancer precision medicine. Recent findings Precision oncology has received federal funding largely due to ‘The Precision Medicine Initiative’. Precision medicine takes into account the inter-individual variability, and allows for tailoring the right medication or the right dose of drug to the best subpopulation of patients who will likely respond to the intervention, thus enhancing therapeutic success and reducing “financial toxicity” to patients, families and caregivers. The National Cancer Institute (NCI) committed US$ 70 million from its fiscal year 2016 budget to advance precision oncology research. Through the ‘Critical Path Initiative’, pharmacometrics has gained an important role in drug development; however, it is yet to find widespread clinical applicability. Summary Stakeholders including clinicians and pharmacometricians need to work in concert to ensure that benefits of model-based approaches are harnessed to personalize cancer care to the individual needs of the patient via better dosing strategies, companion diagnostics, and predictive biomarkers. In medical oncology, where immediate patient care is the clinician’s primary concern, pharmacometric approaches can be tailored to build models that rely on patient data already digitally available in the Electronic Health Record (EHR) to facilitate quick collaboration and avoid additional funding needs. Taken together, we offer a roadmap for the future of precision oncology which is fraught with both challenges and opportunities for pharmacometricians and clinicians alike.

show abstract

Cancer-targeted chemotherapy: Emerging role of the folate anchored dendrimer as drug delivery nanocarrier

Rajani

Borisa

Karanwad

et al. 2020

Pharmaceutical Applications of Dendrimers

View full text Add to dashboard Cite

Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis

Cited by 5 publications

References 44 publications

Complexity and clinical significance of drug–drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT)

Complexity and clinical significance of drug–drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT)

Emerging Roles for Clinical Pharmacometrics in Cancer Precision Medicine

Cancer-targeted chemotherapy: Emerging role of the folate anchored dendrimer as drug delivery nanocarrier

Contact Info

Product

Resources

About